Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: Implications for clinical trial design

Clinical Cancer Research

Volumn 17, Issue 14, 2011, Pages 4705-4718

  Mineharu, Yohei ^a   King, Gwendalyn D ^a   Muhammad, Akm G ^a   Bannykh, Serguei ^a   Kroeger, Kurt M ^a   Liu, Chunyan ^a   Lowenstein, Pedro R ^a,b   Castro, Maria G ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CANCER ANTIBODY; DENDRITIC CELL VACCINE; FLT3 LIGAND; GAMMA INTERFERON; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; TEMOZOLOMIDE; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; AUTOPHAGY; CANCER GENE THERAPY; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CELL LYSATE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE MODEL; DRUG EFFICACY; DRUG POTENTIATION; FREEZING; GENETIC ENGINEERING; GLIOBLASTOMA; HUMORAL IMMUNITY; IMMUNOGENICITY; METHODOLOGY; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; RAT; THAWING; TREATMENT OUTCOME; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ADENOVIRIDAE; ANIMALS; BRAIN NEOPLASMS; CANCER VACCINES; CELL DEATH; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, VIRAL; GENE THERAPY; GENETIC VECTORS; GLIOBLASTOMA; RATS; THYMIDINE KINASE; TUMOR MICROENVIRONMENT;

EID: 79960388611     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0915     Document Type: Article

References (50)

1. Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010;16:2443-9.
2. Schmittling RJ, Archer GE, Mitchell DA, Heimberger A, Pegram C, Herndon JE II, et al. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods 2008;339:74-81.
3. Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, Aldape K, et al. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol 2008;10:98-103. (Pubitemid 351250906)
4. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 2008;20:267-75.
5. Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004;10:5316-26. (Pubitemid 39100466)
6. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004;64:4973-9. (Pubitemid 38924545)
7. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005;11:5515-25. (Pubitemid 41060828)
8. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, et al. Gene expression profile correlates with T cell infiltration and survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011;17:1603-15.
9. Walker DG, Laherty R, Tomlinson FH, Chuah T, Schmidt C. Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J Clin Neurosci 2008;15:114-21. (Pubitemid 50017630)
10. Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005;11:4160-7. (Pubitemid 40791581)
11. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28:4722-9.
12. + T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011;29:330-6.
13. FDA. Vaccines, blood & biologics; cellular & gene therapy products; approved products: PROVENGE® (sipuleucel-T). Vol. 2011. Rockville, MD: FDA; 2010.
14. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94. (Pubitemid 46638945)
15. Kantoff P, Higano CS, Shore ND, Berge ER, Eric J, Small MD, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
16. Ali S, King GD, Curtin JF, Candolfi M, Xiong W, Liu C, et al. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res 2005;65:7194-204. (Pubitemid 41161250)
17. Curtin JF, Candolfi M, Fakhouri TM, Liu C, Alden A, Edwards M, et al. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One 2008;3:e1983.
18. Curtin J, Liu N, Candolfi M, Xiong W, Assi A, Yagiz K, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 2009;6:e10.
19. Curtin JF, King GD, Barcia C, Liu C, Hubert FX, Guillonneau C, et al. Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J Immunol 2006;176:3566-77. (Pubitemid 43364004)
20. Ali S, Curtin JF, Zirger JM, Xiong W, King GD, Barcia C, et al. Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther 2004;10:1071-84. (Pubitemid 39625251)
21. Candolfi M, Yagiz K, Foulad D, Alzadeh GE, Tesarfreund M, Muhammad AK, et al. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res 2009;15:4401-14.
22. King GD, Muhammad AKM, Curtin JF, Barcia C, Puntel M, Liu C, et al. Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro Oncol 2008;10:19-31. (Pubitemid 351250897)
23. King GD, Kroeger KM, Bresee CJ, Candolfi M, Liu C, Manalo CM, et al. Flt3L in combination with HSV1-TK mediated gene therapy reverses brain tumor-induced behavioral deficits. Mol Ther 2008;16:682-90. (Pubitemid 351426169)
24. King G, Muhammad AKM G, Larocque D, Kelson K, Xiong W, Liu C, et al. Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neo-antigen. Mol Ther 2011 Apr 19. [Epub ahead of print].
25. Starck L, Scholz C, Blankenstein T, Dorken B, Daniel PT. Necrotic death but not irradiation abolishes costimulation of T-cell effector functions and survival by CD80-expressing tumor cells. Int J Cancer 2005;116:78-86. (Pubitemid 40827758)
26. Scheffer SR, Nave H, Korangy F, Schlote K, Pabst R, Jaffee EM, et al. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer 2003;103:205-11. (Pubitemid 35461512)
27. Liu K, Nussenzweig MC. Origin and development of dendritic cells. Immunol Rev 2011;234:45-54.
28. Marcusson-Stahl M, Cederbrant K. A flow-cytometric NK-cytotoxicity assay adapted for use in rat repeated dose toxicity studies. Toxicology 2003;193:269-79. (Pubitemid 37355979)
29. Ghulam Muhammad AK, Candolfi M, King GD, Yagiz K, Foulad D, Mineharu Y, et al. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res 2009;15:6113-27.
30. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature 2011;469:323-35.
31. Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, Sphicas E, et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 2001;61:439-44.
32. Tasdemir E, Galluzzi L, Maiuri MC, Criollo A, Vitale I, Hangen E, et al. Methods for assessing autophagy and autophagic cell death. Methods Mol Biol 2008;445:29-76.
33. Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct 1998;23:33-42. (Pubitemid 28223394)
34. Mizushima N. Methods for monitoring autophagy using GFP-LC3 transgenic mice. Methods Enzymol 2009;452:13-23.
35. Yan H, Miyagi T, Satoh E, Sugiura W, Yamamoto N, Kimura H. Phenotype and function of GM-CSF independent dendritic cells generated by long-term propagation of rat bone marrow cells. Cell Immunol 2004;229:117-29. (Pubitemid 39330219)
36. Brissette-Storkus CS, Kettel JC, Whitham TF, Giezeman-Smits KM, Villa LA, Potter DM, et al. Flt-3 ligand (FL) drives differentiation of rat bone marrow-derived dendritic cells expressing OX62 and/or CD161 (NKR-P1). J Leukoc Biol 2002;71:941-9.
37. Weigel BJ, Nath N, Taylor PA, Panoskaltsis-Mortari A, Chen W, Krieg AM, et al. Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses. Blood 2002;100:4169-76. (Pubitemid 35396885)
38. Cohen PA, Koski GK, Czerniecki BJ, Bunting KD, Fu XY, Wang Z, et al. STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells. Blood 2008;112:1832-43.
39. - and type I IFN-producing cells that exhibit selective expression of Toll-like receptors 7 and 9 and strong responsiveness to CpG. J Immunol 2004;172:7485-94.
40. Joffre O, Nolte MA, Sporri R, Reis e Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev 2009;227:234-47.
41. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009;9:353-63.
42. Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol 2006;176:157-64. (Pubitemid 43023259)
43. Brusa D, Garetto S, Chiorino G, Scatolini M, Migliore E, Camussi G, et al. Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity. Vaccine 2008;26:6422-32.
44. Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L, et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 2009;14:364-75.
45. Cui Q, Tashiro S, Onodera S, Minami M, Ikejima T. Autophagy preceded apoptosis in oridonin-treated human breast cancer MCF-7 cells. Biol Pharm Bull 2007;30:859-64. (Pubitemid 46708626)
46. Thorburn J, Horita H, Redzic J, Hansen K, Frankel AE, Thorburn A. Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ 2009;16:175-83.
47. Kawakami M, Kawakami K, Puri RK. Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts. Mol Cancer Ther 2002;1:999-1007.
48. Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M, et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 2001;61:3698-703. (Pubitemid 32694982)
49. Xiong W, Candolfi M, Liu C, Muhammad AK, Yagiz K, Puntel M, et al. Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial. PLoS One 2010;5:e11074.
50. Parajuli P, Mosley RL, Pisarev V, Chavez J, Ulrich A, Varney M, et al. Flt3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets. Exp Hematol 2001;29:1185-93. (Pubitemid 32927219)